Strategic Situation 02
Leading a Global BLA and EU MAA Programme Through Submission Readiness
Strategic Situation 02
01
04
Interim Leadership · Global US BLA / EU MAA · Cross-Functional Governance · Filing Strategy
02
04
Situation
A clinical-stage company preparing for its first filing lacked a dedicated regulatory function. With a submission timeline in place and multiple functions needing alignment, experienced regulatory leadership was required to develop the filing strategy and lead the cross-functional team through submission.
03
04
Contribution
Provided interim global regulatory leadership through the US BLA and EU MAA process, developing the filing plan, establishing cross-functional governance, managing health authority interactions, and guiding the organisation through its first major European regulatory submissions.
04
04
Business consequence
Protecting programme timelines, reducing filing risk, and preserving asset value through submission, a critical inflection point for investor confidence and future market access.
03
03
How we supported the client
To support the client, we performed a gap analysis to identify critical resource gaps. We then closed some of these gaps by leveraging our network. We educated the team on filing requirements, processes, and potential critical steps. We developed a tailored filing plan, filing timetable, and key deliverables. We led the filing team meetings and managed ad-hoc issues on an ongoing basis.

Our support helped the client to successfully submit their MAA. We provided them with the guidance, expertise, and resources they needed to navigate the complex regulatory landscape and achieve their goals.

Strategic 
Regulatory
Advice
Interactions with Health Authorities
Submission
Management
Marketing
Authorisation
Application
Client quote
Stephanie @therainnova has been instrumental in guiding us through all aspects of the EU, US and MHRA filing process in her role as interim Head of Regulatory Affairs. She is a highly knowledgeable and experienced senior regulatory affairs leader with a dedication to meet the client`s deadlines and needs.
Dario Eklund
CEO, Santhera Pharmaceuticals
Client quote
therainnova has supported us in our EU MAA submission. Their swift and ad hoc support in preparing tabulated summaries for the EU MAA showcases their unwavering commitment to enable our timely MAA submission. We were very glad and thankful about their ad hoc support.
Omar Lahlou
Director Regulatory Affairs
Allecra Therapeutics
Share this case study:
© therainnova AG 2026
Follow
Terms and Conditions
Privacy Policy
Design by: G Design Studio
Code: codr.run

© therainnova AG 2026